Literature DB >> 34849288

Diastolic function in patients with heart failure with preserved ejection fraction and atrial fibrillation: impact of diabetes.

Ruxandra-Nicoleta Horodinschi1,2, Camelia Cristina Diaconu1,2.   

Abstract

INTRODUCTION: The objective of our study was to evaluate the severity of diastolic dysfunction in patients with heart failure with preserved ejection fraction (HFpEF), atrial fibrillation (AF) and type 2 diabetes mellitus (T2DM) compared to those with HFpEF and AF without DM.
MATERIAL AND METHODS: This is an observational, prospective, case-control study. We selected 720 patients with heart failure consecutively admitted between March 2019-December 2020, of whom 253 patients with AF. After applying the inclusion/exclusion criteria, 105 subjects remained in the study. The patients were divided into two groups, according to the presence of T2DM: group A (39 patients with T2DM, 37.14%), group B (66 patients without T2DM, 62.85%). 2D transthoracic echocardiography was performed in all patients. The study was approved by the Ethics Committee of the hospital. Statistical analysis was performed using R software, version 4.0.2.
RESULTS: Patients with HFpEF, AF, and T2DM had higher LV filling pressures compared to those without DM (OR = 5.00, 95% CI: 1.77-15.19). Moreover, patients with insulin-requiring T2DM (OR = 6.25, 95% CI: 1.50-25.98) had higher LV filling pressures than those treated with oral antidiabetic drugs (OR = 4.44, 95% CI: 1.37-15.17). We demonstrated that patients with T2DM had higher E/e' ratio (difference -2.78, P 0.0003, 95% CI: -4.24 to -1.31) and lower deceleration time (DT) (difference 23.04, P 0.0002, 95% CI: 11.10-34.97) than those without T2DM.
CONCLUSIONS: Patients with HFpEF, AF and T2DM have higher LV filling pressures than those without T2DM, suggesting that the presence of T2DM leads to a more severe diastolic dysfunction. AJCD
Copyright © 2021.

Entities:  

Keywords:  Heart failure with preserved ejection fraction; atrial fibrillation; diabetes mellitus; diastolic dysfunction; left ventricular filling pressures

Year:  2021        PMID: 34849288      PMCID: PMC8611268     

Source DB:  PubMed          Journal:  Am J Cardiovasc Dis        ISSN: 2160-200X


  50 in total

Review 1.  Clinical Relevance of the Spectral Tissue Doppler E/e' Ratio in the Management of Patients with Atrial Fibrillation: a Comprehensive Review of the Literature.

Authors:  Stephane Arques
Journal:  J Atr Fibrillation       Date:  2018-08-31

Review 2.  Heart Failure With Preserved Ejection Fraction in Diabetes: Mechanisms and Management.

Authors:  Patrick Meagher; Mohamed Adam; Robert Civitarese; Antoinette Bugyei-Twum; Kim A Connelly
Journal:  Can J Cardiol       Date:  2018-03-02       Impact factor: 5.223

Review 3.  Diabetic cardiomyopathy: An expression of stage B heart failure with preserved ejection fraction.

Authors:  Carolyn Sp Lam
Journal:  Diab Vasc Dis Res       Date:  2015-04-23       Impact factor: 3.291

4.  Chronic heart failure and type 2 diabetes mellitus: The last battle?

Authors:  Mark T Kearney
Journal:  Diab Vasc Dis Res       Date:  2015-07       Impact factor: 3.291

5.  The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: the Strong Heart Study.

Authors:  J E Liu; V Palmieri; M J Roman; J N Bella; R Fabsitz; B V Howard; T K Welty; E T Lee; R B Devereux
Journal:  J Am Coll Cardiol       Date:  2001-06-01       Impact factor: 24.094

6.  EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population.

Authors:  Markku S Nieminen; Dirk Brutsaert; Kenneth Dickstein; Helmut Drexler; Ferenc Follath; Veli-Pekka Harjola; Matthias Hochadel; Michel Komajda; Johan Lassus; Jose Luis Lopez-Sendon; Piotr Ponikowski; Luigi Tavazzi
Journal:  Eur Heart J       Date:  2006-09-25       Impact factor: 29.983

7.  Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction).

Authors:  Søren L Kristensen; Ulrik M Mogensen; Pardeep S Jhund; Mark C Petrie; David Preiss; Sithu Win; Lars Køber; Robert S McKelvie; Michael R Zile; Inder S Anand; Michel Komajda; John S Gottdiener; Peter E Carson; John J V McMurray
Journal:  Circulation       Date:  2017-01-04       Impact factor: 29.690

8.  Left ventricular diastolic dysfunction in the early stage of chronic kidney disease.

Authors:  Takenori Otsuka; Makoto Suzuki; Hisao Yoshikawa; Kaoru Sugi
Journal:  J Cardiol       Date:  2009-07-09       Impact factor: 3.159

Review 9.  A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.

Authors:  Walter J Paulus; Carsten Tschöpe
Journal:  J Am Coll Cardiol       Date:  2013-05-15       Impact factor: 24.094

10.  Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry.

Authors:  Marc Klapholz; Matthew Maurer; April M Lowe; Frank Messineo; Jay S Meisner; Judith Mitchell; Jill Kalman; Robert A Phillips; Richard Steingart; Edward J Brown; Robert Berkowitz; Robert Moskowitz; Anita Soni; Donna Mancini; Rachel Bijou; Khashayar Sehhat; Nikita Varshneya; Marrick Kukin; Stuart D Katz; Lynn A Sleeper; Thierry H Le Jemtel
Journal:  J Am Coll Cardiol       Date:  2004-04-21       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.